RxDoctor Payments Data

Delana Wardlaw, MD

Family Medicine · Philadelphia, PANPI 1851489405

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 46 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$216
  • GSK$173
  • Exact Sciences$148
  • Regeneron$133
  • AstraZeneca$117
  • Boehringer Ingelheim$114
  • plus $344 from 9 others

What the payments were for

  • Food & beverage$1,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,246 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,566
Medicare patients
93
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate144$118,599
TrulicityDulaglutide102$110,609
EliquisApixaban69$60,811
OzempicSemaglutide48$49,633
FarxigaDapagliflozin Propanediol42$46,321
JardianceEmpagliflozin17$19,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,421
Incruse ElliptaUmeclidinium Bromide31$10,629
XareltoRivaroxaban13$10,437
Lantus SolostarInsulin Glargine,hum.Rec.Anlog96$10,341
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,375
Atorvastatin Calcium646$9,286
TradjentaLinagliptin18$8,930
Breo ElliptaFluticasone/Vilanterol19$8,761
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$7,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Dulera$17$124,367159 claims
Lilly USA, LLCTrulicity$67$110,609102 claims
Novo NordiskOzempic$66$49,63348 claims
AstraZenecaFarxiga$117$46,32142 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$173$43,18782 claims
Boehringer IngelheimJardiance, Tradjenta$114$28,37835 claims
Johnson & JohnsonXarelto$216$10,43713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →